Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1961 1
1967 2
1968 2
1969 1
1970 2
1971 2
1972 4
1973 2
1974 4
1975 4
1976 5
1977 2
1979 2
1981 1
1982 1
1983 4
1984 1
1985 1
1986 3
1987 3
1989 3
1990 3
1991 2
1992 5
1993 4
1994 1
1995 2
1996 4
1997 2
1998 4
1999 9
2000 5
2001 10
2002 4
2003 10
2004 8
2005 5
2006 8
2007 10
2008 5
2009 9
2010 6
2011 13
2012 9
2013 9
2014 11
2015 21
2016 8
2017 10
2018 10
2019 12
2020 11
2021 9
2022 4
2023 7
2024 10
2025 11
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.
Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I. Loftus EV Jr, et al. Among authors: duncan b. J Crohns Colitis. 2025 Sep 7;19(8):jjaf138. doi: 10.1093/ecco-jcc/jjaf138. J Crohns Colitis. 2025. PMID: 40704669 Free PMC article. Clinical Trial.
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.
Vermeire S, Colombel JF, Danese S, Panaccione R, Peyrin-Biroulet L, Beck K, Chaparro M, Gisbert JP, Dubcenco E, Klaff J, Naling G, Ford S, Remple V, Joshi N, Suravaram S, Duncan B, Wang Y, Wick-Urban B, Loftus EV. Vermeire S, et al. Among authors: duncan b. J Crohns Colitis. 2026 Jan 9;20(1):jjaf198. doi: 10.1093/ecco-jcc/jjaf198. J Crohns Colitis. 2026. PMID: 41264726 Free PMC article. Clinical Trial.
Chlamydia screening and sexual health.
Hart GJ, Duncan B, Fenton KA. Hart GJ, et al. Among authors: duncan b. Sex Transm Infect. 2002 Dec;78(6):396-7. doi: 10.1136/sti.78.6.396. Sex Transm Infect. 2002. PMID: 12473797 Free PMC article. No abstract available.
Satellite Monitoring for Air Quality and Health.
Holloway T, Miller D, Anenberg S, Diao M, Duncan B, Fiore AM, Henze DK, Hess J, Kinney PL, Liu Y, Neu JL, O'Neill SM, Odman MT, Pierce RB, Russell AG, Tong D, West JJ, Zondlo MA. Holloway T, et al. Among authors: duncan b. Annu Rev Biomed Data Sci. 2021 Jul 20;4:417-447. doi: 10.1146/annurev-biodatasci-110920-093120. Epub 2021 Jun 1. Annu Rev Biomed Data Sci. 2021. PMID: 34465183 Review.
miRNA/mRNA analysis of increased TGF-β pathways drive epithelial-mesenchymal transition and regulatory T cell differentiation.
Darville T, Sun X, Zhang Y, O'Connell CM, Mokashi N, Tang W, Bhardwaj A, Duncan B, Andrews CW Jr, Weisenfeld H, Zheng X. Darville T, et al. Among authors: duncan b. bioRxiv [Preprint]. 2025 Jun 26:2025.06.23.661210. doi: 10.1101/2025.06.23.661210. bioRxiv. 2025. Update in: Front Immunol. 2026 Mar 06;17:1679688. doi: 10.3389/fimmu.2026.1679688. PMID: 40667343 Free PMC article. Updated. Preprint.
Hydrogen treatment: a novel option in liver diseases.
Shi J, Duncan B, Kuang X. Shi J, et al. Among authors: duncan b. Clin Med (Lond). 2021 Mar;21(2):e223-e227. doi: 10.7861/clinmed.2020-0370. Clin Med (Lond). 2021. PMID: 33762390 Free PMC article. Review.
309 results